AI-based drug discovery and target licensing deals totaled $47.1 billion in the first half of 2026 alone, according to deal-tracking firm DealForma, already surpassing the $44.6 billion recorded for the entirety of 2025 and signaling an acceleration in pharmaceutical industry confidence in artificial intelligence’s ability to reshape drug development economics. The figure encompasses a wave of mega-deals including Eli Lilly’s $2.75 billion partnership with Insilico Medicine, AstraZeneca’s roughly $1.5 billion deal with insitro, and Takeda’s $600 million Insilico agreement.
What’s Driving the Acceleration
Pharmaceutical companies have grown more willing to commit substantial capital to AI drug discovery partnerships as several AI-discovered candidates have successfully advanced into human clinical trials, providing concrete proof points beyond the theoretical promise that dominated AI drug discovery discourse just a few years ago. Insilico Medicine’s own AI-discovered idiopathic pulmonary fibrosis treatment reaching Phase 2 trials faster than typical industry timelines has been frequently cited as evidence the technology can deliver real development speed advantages, not just computational novelty.
Who’s Doing the Deals
Major pharmaceutical companies including Eli Lilly, AstraZeneca, Takeda and Pfizer have all signed substantial AI drug discovery partnerships in 2026, spreading their bets across multiple AI platform providers including Insilico Medicine, insitro and Chai Discovery rather than concentrating resources with a single partner. This diversification strategy reflects genuine uncertainty about which AI drug discovery approaches will prove most successful, with pharmaceutical companies apparently preferring to hedge across several platforms rather than risk being left behind if a single bet underperforms.
The Milestone-Based Deal Structure
Nearly all of these large AI drug discovery deals are structured around milestone payments tied to successful progression through specific development stages, meaning the eye-catching total deal values reported in headlines represent potential maximum payouts rather than guaranteed upfront cash, a structure that lets pharmaceutical companies manage risk while still giving AI platform providers meaningful upside if their candidates succeed. This structure has made direct comparison between deals somewhat difficult, since the ratio of upfront payment to total potential value varies significantly across different agreements.
The Gap Between Deal Value and Proven Results
Despite the massive capital commitments, no AI-discovered drug has yet received full FDA approval as of October 2026, a gap between dealmaking enthusiasm and regulatory validation that some industry skeptics argue reflects speculative momentum rather than demonstrated returns. Proponents counter that drug development timelines inherently span many years regardless of discovery method, meaning the absence of full approvals so far simply reflects how recently the current generation of AI-discovered candidates entered clinical testing rather than any failure of the underlying technology.
How Smaller AI Drug Discovery Companies Are Faring
The concentration of mega-deals among a handful of well-established AI drug discovery platforms like Insilico Medicine and insitro has made it increasingly difficult for smaller, newer AI drug discovery startups to secure comparable partnerships, even as overall industry investment climbs, creating a bifurcated market where a few leading platforms capture the vast majority of pharmaceutical partnership capital. Some smaller players have pivoted toward narrower therapeutic niches or specific technical capabilities, such as protein structure prediction or toxicity modeling, to differentiate themselves from the broader platforms competing for the largest pharmaceutical partnerships.
What’s Next
With 2026’s first-half total already exceeding all of 2025’s deal value, industry trackers expect the full-year 2026 figure to set a new annual record for AI drug discovery dealmaking, assuming the current pace of major pharmaceutical partnerships continues through the remainder of the year. The more consequential question for the industry’s long-term trajectory is whether 2027 and 2028 will finally produce the first full FDA approvals for AI-discovered drugs, a milestone that would meaningfully validate the current dealmaking boom rather than leaving it dependent on continued investor and pharmaceutical company faith in the technology’s eventual payoff.
Photo: Artem Podrez / PEXELS via Pexels
